Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China

Tempest Therapeutics, Inc.

2025-Q2 EPS reported -$5.17

Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.
Net loss Q2 2025: $7.9M ($2.07 per share) vs $9.6M ($5.52) in Q2 2024.
R&D expense Q2 2025: $3.9M, down from $5.8M due to re-prioritization toward strategic alternatives.
Received clearance to start pivotal trial of amezalpat combo for first-line HCC in China; EMA orphan drug designation granted.
Completed $4.6M registered direct offering in June 2025; net proceeds $4.1M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.